Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.

Chronic Myeloid Leukemia (CML) Clinical Trial

— MACS1881  

Official title:

A Phase II, Non Randomized, Open Label, Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01605981
• Other study ID #: CAMN107EBR06
• Status: Withdrawn
• Phase: Phase 4
• First received: May 23, 2012
• Last updated: April 19, 2017
• Start date: February 2014
• Est. completion date: January 2017

Study information

• Verified date: June 2014
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label, non randomized, prospective, multicenter, phase II clinical trial evaluating nilotinib 400 mg BID for the treatment of newly diagnosed CML-AP patients.

Patients enrolled into the study will receive 400mg of nilotinib, orally, twice daily (800mg/day)

Description:

Patients will be evaluated for safety throughout the study and for response every month for the first 3 months, then every 3 months thereafter up to month 24.

BCR-ABL transcripts measurement by QRT-PCR and mutation analyses will be done on peripheral blood samples and cytogenetic analyses on bone marrow aspirates.

Laboratory tests (hematology, blood chemistry), ECG and physical examination will be done on every visit.

Drug pharmacokinetics will be assessed in this study. For the screening Baseline periods, see chart attached

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 2017
• Est. primary completion date: January 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients age > 18 years old;

• Diagnosis of Chronic Myeloid leukemia in Accelerated Phase (CML-AP);

• Patients with CML-AP(See Appendix 1) within 3 months of diagnosis (date of initial diagnosis is the date of first reported cytogenetic analysis). Standard conventional cytogenetic analysis must be done on bone marrow. FISH cannot be used for purpose of inclusion;

• Patients with atypical BCR-ABL transcripts are eligible (transcripts other then b2a2 an b3a2);

• No previous treatment with any antileukemic drugs with the exception of hydroxyurea (HU) and/or anagrelide. In emergent cases where the patient requires disease management while awaiting study start, commercial supplies of Gleevec/Glivec at any dose may be prescribed to the patient but for no longer than 2 weeks in duration;

• ECOG 0,1 or 2;

• Normal serum levels > LLN (lower limit of normal) or corrected to within normal limits with supplements, prior to the first dose of study medication, of potassium magnesium and calcium;

• AST and ALT < 2.5 x ULN (upper limit of normal) or < 5.0 x ULN if considered due to leukemia;

• Alkaline phosphatase < 2.5 x ULN, unless considered due to leukemia;

• Total bilirubin < 1.5 x ULN;

• Serum lipase and amylase < 1.5 x ULN;

• Written informed consent prior to any study procedures being performed.

Exclusion Criteria:

• Patients in Chronic and Blastic Phases.

• Patients who are considered Ph negative because they do not have a confirmed cytogenetic diagnosis of Philadelphia Ph+ chromosome (9;22 translocation) in > 20 metaphases.

• Treatment with tyrosine kinase inhibitors or other antileukemic agents or treatments (including HSCT) for longer than 2 weeks, with the exception of HU and/or anagrelide

• Previously documented T315I mutations;

• Uncontrolled congestive heart failure or hypertension;

• Myocardial infarction or unstable angina pectoris within past 12 months;

• Significant arrhythmias, including history or presence of clinically significant ventricular or atrial tachyarrhythmias, clinically significant bradycardias, long QT syndrome and/or QTc > 450 msec on screening ECG (using the QTcF formula). Patients with complete LBBB;

• History of confirmed acute or chronic pancreatitis;

• Other concurrent uncontrolled medical conditions (e.g. uncontrolled diabetes, active or uncontrolled infections, acute or chronic liver and renal disease) that could cause unacceptable safety risks or compromise compliance with the protocol;

• Impaired gastrointestinal function or GI disease that may alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting and diarrhea, malabsorption syndrome, small bowel resection or gastric bypass surgery);

• Patients with another primary malignancy that is currently clinically significant or requires active intervention;

• Concomitant medications with potential QT prolongation (See link for complete list:

http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm);

• Concomitant medications known to interact with CYP450 isoenzymes (CYP 3A4, CYP2C9, CYP2C8, (See link for complete list (http://medicine.iupui.edu/flockhart/table.htm);

• History of significant congenital or acquired bleeding disorder unrelated to cancer;

• Patients who have undergone major surgery = 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy;

• Patients who are pregnant or breastfeeding or adults of reproductive potential not employing an effective method of birth control. (Women of childbearing potential must have a negative serum pregnancy test within 48 hrs prior to administration of nilotinib). Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients must agree to employ an effective barrier method of birth control throughout the entire study and up to 3 months following discontinuation of study drug;

• Treatment with any hematopoietic colony-stimulating growth factors (e.g. G-CSF, GM-CSF) 1 week prior to starting study drug;

• Treatment with other investigational agents (defined as not used in accordance with the approved indication) within 30 days of Day 1;

• Patients unwilling or unable to comply with the protocol.

Note:

Patients who did not meet one or more inclusion or exclusion criteria may be re-screened for this study at a later time if the medical condition is transient and has been appropriately treated (provided they enter the study within 3 months of diagnosis). Date of diagnosis is defined as date of confirmatory bone marrow cytogenetic analysis.

Related Conditions & MeSH terms

• Chronic Myeloid Leukemia (CML)
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Intervention

Drug:
• AMN107

Locations

Country	Name	City	State
Brazil	Novartis Investigative Site	Belo Horizonte	MG
Brazil	Novartis Investigative Site	Campinas	SP
Brazil	Novartis Investigative Site	Cuiaba	MS
Brazil	Novartis Investigative Site	Curitiba	PR
Brazil	Novartis Investigative Site	Florianopolis	SC
Brazil	Novartis Investigative Site	Fortaleza	CE
Brazil	Novartis Investigative Site	Goiania	GO
Brazil	Novartis Investigative Site	Jaú	SP
Brazil	Novartis Investigative Site	Niterói	RJ
Brazil	Novartis Investigative Site	Porto Alegre	RS
Brazil	Novartis Investigative Site	Porto Alegre	Porto Alegre-RS
Brazil	Novartis Investigative Site	Rio de Janeiro	RJ
Brazil	Novartis Investigative Site	Santo Andre	SP
Brazil	Novartis Investigative Site	Santos	SP
Brazil	Novartis Investigative Site	São José	Sao Paulo
Brazil	Novartis Investigative Site	Sao Paulo
Brazil	Novartis Investigative Site	São Paulo	SP
Brazil	Novartis Investigative Site	São Paulo	SP

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the safety and tolerability profile of nilotinib in newly diagnosed CML-AP	The toxicity criteria will be evaluated according to National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 3.0.	12 month
Primary	To test the efficacy of nilotinib 400 mg BID	To test the efficacy of nilotinib 400 mg BID in inducing complete cytogenetic response (CCyR) at 12 months in newly diagnosed CML-AP patients	12 months
Secondary	Evaluate the rate of complete hematologic response (CHR)	Evaluate the rate of complete hematologic response (CHR) with nilotinib 400 mg BID at 3 months.	3 months
Secondary	Evaluate the Quality of Life	Evaluate the Quality of Life by FACT-Leu Version 4 questionnaire at 3, 6, 9, 12, 15, 18 and 24 months.	3, 6, 9, 12, 15, 18 and 24 months
Secondary	Evaluate the median time to achieve molecular response	Evaluate the median time to achieve molecular response and the cumulative probability of obtaining molecular response during the first 2 years of treatment. This will be undertaken through the analysis of the best molecular response at 3, 6, 12, 18 and 24 months. MMR will be preferred and it will be defined as a BCR-ABL/ABL ratio = 0.1% IS using RQ-PCR, but any log reduction between 1 and 4,5 logs will be considered a molecular response.	uring the first 2 years of treatment
Secondary	Evaluate the proportion of patients achieving CCyR	Evaluate the proportion of patients achieving CCyR at 3, 6, 12, 18 and 24 months or undetectable BCR-ABL levels at 12, 18 and 24 months as well as the duration of sustained response.	3, 6, 12, 18 and 24 months or undetectable BCR-ABL levels at 12, 18 and 24 months
Secondary	To correlate the probability of reaching MMR, CMR and CCyR	To correlate the probability of reaching MMR, CMR and CCyR with the risk of progression to blastic phase, relapse and overall survival.	2 years